Health Canada
www.hc-sc.gc.ca
Common menu bar links
Association of acute renal failure (severe kidney problems) and reports of cytopenias (low blood cell counts) with PrEXJADE* (deferasirox)
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
(PDF Version - 280 K)Contact: Marketed Health Products Directorate (MHPD)
The Health Products and Food Branch (HPFB) posts on the Health Canada web site safety alerts, public health advisories, press releases and other notices as a service to health professionals, consumers, and other interested parties. These advisories may be prepared with Directorates in the HPFB which includes pre-market and post-market areas as well as market authorization holders and other stakeholders. Although the HPFB grants market authorizations or licenses for therapeutic products, we do not endorse either the product or the company. Any questions regarding product information should be discussed with your health professional.
This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Public Communication
Health Canada Endorsed Important Safety Information on PrEXJADE* (deferasirox)
March 9, 2007
Subject: Severe kidney problems associated with EXJADE* (deferasirox)
Reports of low blood cell counts (cytopenias) with EXJADE* (deferasirox)
Following discussions with Health Canada, Novartis wishes to provide you with updated safety information regarding reports of severe kidney problems and cytopenias (low blood cell counts) with EXJADE*.
EXJADE* is used to treat chronic iron overload caused by blood transfusions for the treatment of anemias for adults, adolescents, and children aged 6 years and over; and in children aged 2 to 5 years who cannot be adequately treated with deferoxamine.
Therapy with EXJADE* should be initiated and maintained by physicians experienced in the treatment of chronic iron overload due to blood transfusions.
- Cases of severe kidney problems (some with fatal outcome) have been reported following the post-marketing use (commercial use) of EXJADE*. For the reports in which the outcome for these critically ill patients was fatal, the involvement of EXJADE* with the kidney problems cannot be excluded, although the fatalities could have been caused by underlying diseases. When EXJADE* was discontinued in the non-fatal cases, the kidney problems improved, which indicates an involvement of EXJADE*.
-
Your kidney function (serum creatinine) should be monitored twice before you start taking EXJADE*. Weekly monitoring will then be done for the first month of treatment, or after a change of treatment, and monitored monthly thereafter. A second test for kidney function (proteinuria) will also be performed monthly. You and your doctor should also ensure that you are well hydrated (drink lots of fluid). Tell your doctor if you produce less urine than usual.
- Some patients have developed blood cell counts that are too low (cytopenias) while on EXJADE* therapy. Most of these patients already had diseases that lead to their low blood cell counts, so the relationship to EXJADE* treatment is uncertain. If you have a disease that might result in abnormal blood cell counts, your doctor should continue routine monitoring of your blood cell counts.
A copy of the Health Care Professional letter and this communication are available on the Health Canada website.
If you have any questions about the above information or about EXJADE* please talk to your doctor, pharmacist, or contact Novartis Pharmaceuticals Canada Inc. at : 1-800-363-8883.
For more information on EXJADE* please consult the Consumer Information document available at 
http://www.novartis.ca.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them, in addition to reports collected from clinical trials. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health products. If you have had a serious or unexpected reaction to EXJADE* you may notify either Novartis Pharmaceuticals Canada Inc. or Health Canada as follows:
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval, (QC) H9S 1A9
Phone: 1-800-363-8883
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
For media inquiries please contact Jason Jacobs at (514) 633-7872.
Sincerely,
original signed by
Pier-Giorgio Fontana, PhD
Vice-President
Regulatory Affairs
Jean-Marie Leclerc, M.D. FRCP(C)
Chief Scientific Officer and Senior Vice-President Clinical and Regulatory Affairs
* EXJADE is a registered trademark.
